menu
    • menu
    [{"orgOrder":0,"company":"Rege Nephro","sponsor":"DCI Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Series B Financing","leadProduct":"Tamibarotene","moa":"RAR-alpha","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro \/ DCI Partners","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ DCI Partners"},{"orgOrder":0,"company":"Rege Nephro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"RAR-alpha","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ Inapplicable"},{"orgOrder":0,"company":"Rege Nephro","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Acquisition","leadProduct":"Tamibarotene","moa":"RAR-alpha","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rege Nephro \/ Rege Nephro","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ Rege Nephro"}]

    Find Clinical Drug Pipeline Developments & Deals by Rege Nephro

    Menu

    Rege Nephro

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rege Nephro

                            Japan arrow
                            Hospitalar
                            Not Confirmed

                            Rege Nephro

                            Japan arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tamibarotene

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Syros Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Rege Nephro Acquires Tamibarotene Assets for U.S. Trials

                            Details : Through the acquisition, Rege Nephro will leverage RN-014 (tamibarotene) related clinical and non-clinical assets from Syros. It is being evaluated for autosomal dominant polycystic kidney disease.

                            Product Name : RN-014

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            April 15, 2025

                            Lead Product(s) : Tamibarotene

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Syros Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rege Nephro

                            Japan arrow
                            Hospitalar
                            Not Confirmed

                            Rege Nephro

                            Japan arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tamibarotene

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : DCI Partners

                            Deal Size : $16.7 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Rege Nephro Completes Series B Funding For Kidney Disease Therapy Trials

                            Details : The funds will be used to advance the clinical trials of RN-014 (tamibarotene), company's retinoic acid receptor (RAR) agonist treatment, in Phase 2 for Autosomal Dominant Polycystic Kidney Disease.

                            Product Name : RN-014

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            July 10, 2024

                            Lead Product(s) : Tamibarotene

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : DCI Partners

                            Deal Size : $16.7 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rege Nephro

                            Japan arrow
                            Hospitalar
                            Not Confirmed

                            Rege Nephro

                            Japan arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tamibarotene

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rege Nephro Enrolls Patients For Phase II Tamibarotene ADPKD Trial

                            Details : RN-014 (tamibarotene), under development for ADPKD, is a retinoic acid receptor (RAR) agonist expected to potently inhibit cyst formation and improve renal function.

                            Product Name : RN-014

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            May 28, 2024

                            Lead Product(s) : Tamibarotene

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth